logo transparent gif
top_left_edge top_white_spacer top_right_edge
Home Latest Stock Forum Topics MyCorner - Personal Stocks Porfolio Stock Lists Forex Investor Insights Investment News Investor Research & Links Dynamic Stock Charting FREE Registration About Us top spacer top spacer
 User Password Auto-Login
Enter Stock
 
righttip
branding

Back
First   < Newer   4321-4340 of 10899   Older>   Last  
Latest Forum Topics / Biosensors  Post Reply
Is Biosensors a good buy?
Centaur
Veteran
24-Sep-2009 11:32     
 
Centaur About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		A bit disappointed to see price drop despite good leaders trial results though.......
 Useful To Me  Not Useful To Me
keepnosecrets
Master
24-Sep-2009 11:23     
 
keepnosecrets About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Congrats, I'm together with you all the way. My avg much lower, but want to stay on for a chance to see new highs being set this year, that is if we are in great luck. Huat arh..........everyone vested.Smiley 23
 Useful To Me  Not Useful To Me


AK_Francis
Supreme
24-Sep-2009 11:05     
 
AK_Francis About Contact  Quote this Post! Style: Fundamental   Mood: cool
Yells: "Happy go lucky, cheers."
  x 1
  x 0

 Alert Admin

TP of FV 74cts. Good blessing loh.

Got it at 57.3 cts avg. Ha ha, 8 cts away liao. No harm to wait for another 8 cts loh. Huat huat.Smiley 23



keepnosecrets      ( Date: 23-Sep-2009 20:50) Posted:



The immediate TP is fair value 74 cents which many of you would not want to go in because now 66 cents, only 8 cents away leh.  So if you are in, you should only be prepared for holding a little longer ya?.  Understand your own financial position.  Would you like 5 to 8 cents profit? You can get it for many other counters and faster too.

But don't underestimate Biosensors for its spiking power. My chart shows it is very strong and will take us by surprise going to where it has not gone before since quite a while oredi.  DYO HAM YOD BOS!!! (Do your own homework and make your own decision buy or sell.)
 Useful To Me  Not Useful To Me
JustForFun
Member
24-Sep-2009 08:49     
 
JustForFun About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

LEADERS Two-Year Results Indicate Improved Safety and Efficacy of Biodegradable Polymer Technology over Conventional Durable Polymers


San Francisco, USA, 23 September 2009 – Biosensors International Group, Ltd (“Biosensors”, “Company”, BIG:SP) today announced the two-year results of the LEADERS trial, which showed an increasing trend towards a safety benefit for the Biosensors Biolimus A9™-eluting stent with abluminal biodegradable polymer (“BES”) compared to Johnson & Johnson’s sirolimus-eluting stent with a durable polymer (“SES”). Results were presented by Professor Volker Klauss as part of the Late Breaking Trial session at the 21st annual Transcatheter Cardiovascular Therapeutics (“TCT”) scientific symposium, sponsored by the Cardiovascular Research Foundation.


“These additional follow-up results from LEADERS confirm that the Biosensors Biolimus A9-eluting stent is safe and effective two years after implantation in an all-comers population reflecting patients we treat in our routine clinical practice”, commented LEADERS Principal Investigator Professor Stephan Windecker, University Hospital, Bern, Switzerland.


In the overall study population there were similar outcomes for BES and SES, with an increasing advantage observed for BES in both Major Adverse Cardiac Events (“MACE”) (BES: 13% vs. SES: 15.4% p=0.18) and Cardiac Death/Myocardial Infarction (BES: 8.3% vs. SES: 9.1% p=0.59) compared with both nine and 12-month results. The differences were not statistically significant. In the high risk sub-group of STEMI patients (ST Elevation Myocardial Infarction), a statistically significant improved MACE rate was demonstrated with BES compared to SES (8.1% vs. 19.3% p<0.01).


Although this was an all-comers study, occurrence of very late stent thrombosis events was rare (BES 0.2% vs. SES 0.5% p=0.73). In the BES group, the two events observed were limited to patients with Saphenous Vein Grafts (“SVG”), who are traditionally excluded from drug-eluting stent trials. Notably, there were no very late stent thrombosis events in BES patients after discontinuation of dual anti-platelet therapy (“DAPT”).


“We are extremely pleased with these long-term results”, concluded Michael Kleine, President & CEO of Biosensors. “They confirm that our drug-eluting stent technology, with its unique combination of anti-restenotic drug and abluminal biodegradable polymer, has created a new industry standard.”


LEADERS (Limus Eluted from A Durable versus ERodable Stent coating), is a multi-centre randomized study in which 1,707 patients eligible for PCI for symptomatic coronary disease received either a Biosensors Biolimus A9™-eluting stent with an abluminal biodegradable polymer coating, or a sirolimus-eluting stent with a durable polymer. Inclusion criteria were broad, reflecting routine clinical practice, without limitations regarding type of coronary vessel, lesion length or number of treated lesions. The nine-month results, presented at the European Society of Cardiology (“ESC”) congress in 2008 and simultaneously published in The Lancet, demonstrated BES to be non-inferior to SES in respect of the primary endpoint, incidence of MACE at nine months. This non-inferiority was confirmed in the 12-month results, at which time a non-significant difference in the rates of stent thrombosis in favor of BES was also observed.


Although funded by Biosensors, LEADERS was independently designed, implemented and analyzed by the study investigators. Moreover, data management and analysis were performed by an independent academic institution.
 Useful To Me  Not Useful To Me
keepnosecrets
Master
23-Sep-2009 20:50     
 
keepnosecrets About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

The immediate TP is fair value 74 cents which many of you would not want to go in because now 66 cents, only 8 cents away leh.  So if you are in, you should only be prepared for holding a little longer ya?.  Understand your own financial position.  Would you like 5 to 8 cents profit? You can get it for many other counters and faster too.

But don't underestimate Biosensors for its spiking power. My chart shows it is very strong and will take us by surprise going to where it has not gone before since quite a while oredi.  DYO HAM YOD BOS!!! (Do your own homework and make your own decision buy or sell.)
 Useful To Me  Not Useful To Me


starlene
Elite
23-Sep-2009 17:06     
 
starlene About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin
meatball wrote:
Biosensor confirm MULTI BaGGER in the long term. Wink
Cheers Very Happy
..1 lot buy up to create new 2009's high of 66cts


16:59:05 0.655 50,000 B
16:58:56 0.660 1,000 A Razz Razz Razz :P
16:58:44 0.655 125,000 A
16:57:45 0.655 20,000 A
16:57:42 0.655 30,000 A
16:57:37 0.655 20,000 A
16:57:19 0.655 5,000 B
16:57:06 0.655 25,000 A
16:56:54 0.655 30,000 A
16:56:40 0.655 20,000 B
16:56:20 0.655 20,000 B
16:56:19 0.655 50,000 B
16:56:09 0.655 10,000 B
16:55:15 0.655 5,000 A
16:55:11 0.655 1,000 A
16:54:52 0.655 10,000 A
16:54:44 0.655 4,000 A
16:54:31 0.655 16,000 A
16:54:19 0.655 200,000 A
16:52:51 0.655 30,000 A
16:51:48 0.655 9,000 B
16:51:40 0.655 20,000 B
16:51:13 0.655 10,000 B
16:51:05 0.655 5,000 B
16:50:55 0.655 10,000 B
16:50:45 0.655 12,000 A
16:50:21 0.655 38,000 B
16:50:18 0.655 10,000 B
16:50:09 0.655 182,000 A
16:50:02 0.655 100,000 A
16:49:39 0.655 15,000 A
16:49:37 0.655 13,000 A
16:49:36 0.655 9,000 A
16:49:35 0.655 180,000 A
16:49:10 0.655 20,000 A
16:49:01 0.655 50,000 A
16:49:00 0.655 100,000 A
16:48:56 0.655 30,000 A
16:48:28 0.655 50,000 A
16:47:52 0.655 10,000 A
16:46:49 0.655 100,000 A
16:46:29 0.655 23,000 A
16:45:07 0.650 20,000 B
16:44:49 0.655 1,000 A
16:44:47 0.655 10,000 A
16:44:21 0.655 50,000 A
16:42:37 0.650 100,000 B
16:40:29 0.655 10,000 A
16:39:05 0.655 50,000 A
16:38:08 0.650 20,000 B
16:38:04 0.655 500,000 A
16:37:17 0.650 8,000 A
16:36:43 0.650 50,000 A
16:36:34 0.650 50,000 A
16:36:19 0.650 10,000 A
16:35:41 0.650 20,000 A
16:34:37 0.650 15,000 A
16:34:16 0.650 1,000 A
16:33:28 0.650 2,000 A
16:32:58 0.650 10,000 A
16:31:44 0.650 30,000 A
16:31:38 0.650 300,000 A
16:29:13 0.650 50,000 A
16:29:10 0.650 1,000 A
16:28:22 0.650 50,000 A
16:28:20 0.650 100,000 A
16:27:03 0.650 50,000
 Useful To Me  Not Useful To Me
AK_Francis
Supreme
23-Sep-2009 11:57     
 
AK_Francis About Contact  Quote this Post! Style: Fundamental   Mood: cool
Yells: "Happy go lucky, cheers."
  x 0
  x 0

 Alert Admin

Ref to DIG making $ on Citi Grp:

AK dun ask people to buy stock, but ds burger got potential. AK view only. 2Y apply. Mood good loh, as Gent SP cheong.



keepnosecrets      ( Date: 23-Sep-2009 08:34) Posted:

Biosensors is chartists' baby, breaking out, up and up.  Missed the 62 cents recently. Waited in queue but did not get.  Will plough some profits into this.
 Useful To Me  Not Useful To Me
keepnosecrets
Master
23-Sep-2009 08:34     
 
keepnosecrets About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Biosensors is chartists' baby, breaking out, up and up.  Missed the 62 cents recently. Waited in queue but did not get.  Will plough some profits into this.
 Useful To Me  Not Useful To Me


starlene
Elite
22-Sep-2009 23:48     
 
starlene About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin
Tue Sep 22, 2009 11:19 pm    Post subject: Reply with quote Edit/Delete this post Delete this post
Looks > promising,around 3.48pm today hit 2009's high of 65cts
Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz Razz

17:05:03 0.640 310,000 B
16:58:56 0.640 13,000 B
16:57:11 0.645 1,000 A
16:53:15 0.645 15,000 A
16:52:33 0.645 30,000 A
16:45:53 0.645 5,000 A
16:45:52 0.645 5,000 A
16:41:17 0.645 50,000 A
16:36:46 0.645 10,000 A
16:32:59 0.645 40,000 A
16:25:32 0.645 30,000 A
16:23:03 0.645 2,000 A
16:22:12 0.645 50,000 A
16:21:56 0.645 50,000 A
16:21:35 0.645 30,000 A
16:20:13 0.645 10,000 A
16:19:38 0.645 2,000 A
16:18:51 0.645 5,000 A
16:18:23 0.645 15,000 A
16:17:31 0.645 30,000 A
16:17:16 0.645 45,000 B
16:16:50 0.645 18,000 A
16:16:36 0.645 15,000 A
16:16:33 0.645 30,000 A
16:15:12 0.645 1,000 A
16:14:38 0.645 136,000 B
16:12:59 0.645 64,000 A
16:12:55 0.645 136,000 B
16:12:15 0.645 30,000 B
16:11:58 0.645 50,000 B
16:11:56 0.645 134,000 A
16:10:47 0.645 36,000 B
16:09:26 0.645 4,000 A
16:09:14 0.645 20,000 A
16:09:03 0.645 10,000 A
16:08:45 0.645 476,000 B
16:07:22 0.650 10,000 A
16:05:19 0.650 10,000 A
16:03:55 0.650 5,000 A
16:02:19 0.645 10,000 B
16:01:08 0.645 100,000 B
16:00:47 0.645 9,000 B
16:00:46 0.650 200,000 A
16:00:32 0.645 20,000 B
15:59:37 0.645 11,000 B
15:57:59 0.650 10,000 A
15:57:27 0.650 20,000 A
15:57:04 0.645 10,000 B
15:56:54 0.645 10,000 B
15:56:22 0.645 50,000 B
15:56:01 0.645 20,000 B
15:55:13 0.645 20,000 B
15:55:12 0.645 100,000 B
15:54:34 0.645 15,000 B
15:53:29 0.645 10,000 B
15:53:29 0.645 10,000 B
15:52:52 0.645 200,000 B
15:50:56 0.645 50,000 B
15:50:52 0.650 5,000 A
15:48:22 0.650 5,000 A
15:47:55 0.645 15,000 B
15:46:43 0.645 60,000 B
15:46:29 0.645 100,000 B
15:45:36 0.645 20,000 B
15:44:06 0.645 4,000 A
15:43:57 0.645 1,000 B
15:43:00 0.645 50,000 B
15:42:30 0.645 16,000 B
15:42:29 0.645 20,000 A
15:42:25 0.645 10,000 A
15:42:24 0.645 30,000 A
15:42:20 0.645 10,000 A
15:42:06 0.645 40,000 A
15:41:59 0.645 15,000 A
15:41:41 0.645 138,000 B
15:41:39 0.645 162,000 B
15:41:24 0.645 50,000 B
15:38:42 0.650 500,000 A
15:38:31 0.645 10,000 B
15:37:51 0.645 20,000 B
15:37:48 0.645 10,000 B
15:37:18 0.645 200,000 B
15:36:35 0.645 178,000 B
15:36:28 0.645 110,000 B
15:36:13 0.650 100,000 A
15:36:03 0.650 31,000 A
15:36:00 0.650 30,000 A
15:35:59 0.650 300,000 A
15:35:59 0.650 50,000 A
15:35:40 0.650 40,000 A
15:35:32 0.650 100,000 A
15:35:08 0.645 100,000 B
15:34:58 0.645 20,000 B
15:34:55 0.645 70,000 A
15:34:54 0.645 35,000 A
15:34:53 0.645 20,000 A
15:34:51 0.645 10,000 A
15:34:50 0.645 30,000 A
15:34:48 0.645 100,000 A
15:34:46 0.645 Razz
 Useful To Me  Not Useful To Me
keepnosecrets
Master
22-Sep-2009 16:27     
 
keepnosecrets About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		But mermaid, genting swept past Big, to win by many cents.

keepnosecrets      ( Date: 22-Sep-2009 15:36) Posted:

Round the home turn, look at Biosensors flying!!
 Useful To Me  Not Useful To Me
keepnosecrets
Master
22-Sep-2009 15:36     
 
keepnosecrets About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Round the home turn, look at Biosensors flying!!
 Useful To Me  Not Useful To Me
JustForFun
Member
22-Sep-2009 12:19     
 
JustForFun About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Drug-Eluting Stents Safe, Effective for Treatment of Chronic Total Occlusions



Monday, September 21, 2009


SAN FRANCISCO, CA –  A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The aim of the study, “Drug-Eluting Stents for the Treatment of Chronic Total Occlusion: A Comparison with Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), Biolimus A9 (BES), EPC Capture (ECS) and Everolimus-Eluting Stent (EES): Multicenter Registry in Asia” is to compare the safety and efficacy of SES, PES, ZES, BES, SCS and EES in the treatment of patients with chronic total occlusion (blockage) of cardiac blood vessels. The study will be presented as a poster abstract (TCT-234) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The Moscone Center. 

For the study, researchers led by Sunao Nakamura, MD, performed a prospective analysis of 1,148 patients with 1,253 CTOs treated with different drug-eluting stents (396 SES, 526 PES, 177 ZES, 66 BES, 41 ECS, and 43 EES) in six high volume Asian centers after successful CTO re-canalization was performed.

Dr. Nakamura, who will report on the results of the investigations, is Vice President and Director of the Cardiovascular Center at New Tokyo Hospital as well as Clinical and Visiting Professor of Kumamoto University in Matsudo, Japan. 

The researchers found that the incidence of major adverse cardiac events (MACE) at 30 days was nearly non-existent in patients with CTO lesions treated with drug-eluting stents (0.4% in patients with PES, 0.6% in ZES and 0% in all other categories). MACE at 9 months was 3.6% for those receiving SES, 6.7% for PES, 10.4% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES. Target lesion revascularization (TLR) at 9 months was 3.6% for patients who received SES, 6.7% for PES, 10.4% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES.   

In addition, patients treated with SES, BES and EES showed a lesser rate of angiographic restenosis compared with other drug-eluting stents at 9 months (4.0% restenosis for patients receiving SES, 6.7% for PES, 12.3% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES).  

In conclusion, Dr. Nakamura noted that, “The study indicates a good clinical performance of the new BES and EES devices.”

The research team for the study also included Shotaro Nakamura, MD,  New Tokyo Hospital; Hisao Ogawa, MD,  Kumamoto University Hospital, Kumamoto, Japan; Jang-Ho Bae, MD, Konyang University Hospital, Daejeon, Republic of Korea; Yeo Hans Cahyadi, MD, Husada Hospital, Jakarta, Indonesia; Wasan Udayachalerm, MD, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Damras Tresukosol, MD, Her Majesty's Cardiac Center Siriraj Hospital, Bangkok, Thailand; and Sudaratana Tansuphaswadikul, MD, Chest Disease Institute, Bangkok, Thailand.

Source: The Cardiovascular Research Foundation


 
 Useful To Me  Not Useful To Me


JustForFun
Member
22-Sep-2009 12:16     
 
JustForFun About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Researchers Find Drug-Eluting Stents Safe, Effective for PCI in Diabetics



Monday, September 21, 2009


SAN FRANCISCO, CA ─  Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The study, “The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter Registry in Asia,” compared the safety and efficacy of  sirolimus (SES), paclitaxel (PES), zotarolimus ( ZES), biolimus A9 (BES) and everolimus-eluting (EES) stents on the outcome of percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM).

The study will be presented as a poster abstract (TCT-363) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The Moscone Center. Sunao Nakamura, MD, lead investigator for the study, will report on the results of the investigations. Dr. Nakamura is Vice President and Director of the Cardiovascular Center at New Tokyo Hospital as well as Clinical and Visiting Professor of Kumamoto University in Matsudo, Japan.

The investigation consisted of a prospective analysis of 1,373 patients with DM treated with different drug-eluting stents (508 SES, 420 PES, 204 ZES, 120 BES and 121 EES) in six high-volume Asian centers. The study endpoints were the incidence of MACE at 30 days, the restenosis rate at 9 months and target lesion revascularization (TLR) at 9 months.

The incidence of MACE with this study cohort was 0.8% in patients receiving SES, 1.2% in PES, 1.0% in ZES, 0.8% in BES and 0.0% in EES. The restenosis rate at 9 months was 7.9% for those receiving SES, 12.6% for PES, 16.2% for ZES, 5.0% for BES and 6.7% for EES. TLR at 9 months was 6.5% in patients receiving SES, 10.7% with PES, 13.7% with ZES, 5.0% with BES and 4.1% with EES. 

The researchers concluded that the use of drug-eluting stents in patients with DM was safe with low acute complications. Further, patients treated with SES, BES and EES showed a lesser rate of restenosis when compared with other drug-eluting stents.

The research team for the study also included Shotaro Nakamura, MD, New Tokyo Hospital; Hisao Ogawa, MD, Kumamoto University Hospital, Kumamoto, Japan; Jang-Ho Bae, MD, Konyang University Hospital, Daejeon, Republic of Korea;  Yeo Hans Cahyadi, MD, Husada Hospital, Jakarta, Indonesia; Wasan Udayachalerm, MD, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Damras Tresukosol, MD, Her Majesty's Cardiac Center Siriraj Hospital, Bangkok, Thailand; and Sudaratana Tansuphaswadikul, MD, Chest Disease Institute, Bangkok, Thailand.

Source: The Cardiovascular Research Foundation


 
 Useful To Me  Not Useful To Me
MsAloevera
Member
14-Sep-2009 17:36     
 
MsAloevera About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

I Ot two months first =X
 Useful To Me  Not Useful To Me
louis_leecs
Elite
14-Sep-2009 09:24     
 
louis_leecs About Contact  Quote this Post!   Mood: happy
Yells: "half cash"
  x 0
  x 0

 Alert Admin 		cn up sure can down,,,,,,,,,,,,,,let the dust settle first,,,,,,,,,,,,,,,,,,,,,storm havent come,,,,,,,,,,,,,,,,may be soon,,,,,,,,,,,,,,,,,bukit timah hill three week
 Useful To Me  Not Useful To Me
thulasiappan
Senior
14-Sep-2009 08:34     
 
thulasiappan About Contact  Quote this Post! Style: Combined   Mood: cool
Yells: "Just a Beginner in trading"
  x 0
  x 0

 Alert Admin 		Thanks for the divine blessings.

starlene      ( Date: 13-Sep-2009 19:23) Posted:

Long term investors of BIG will be blessed.

 

http://img147.imageshack.us/i/img2900.jpg/



keepnosecrets      ( Date: 09-Sep-2009 16:50) Posted:

Think 74 cents Fair value is just a modest estimate.
 Useful To Me  Not Useful To Me
starlene
Elite
13-Sep-2009 19:23     
 
starlene About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Long term investors of BIG will be blessed.

 

http://img147.imageshack.us/i/img2900.jpg/



keepnosecrets      ( Date: 09-Sep-2009 16:50) Posted:

Think 74 cents Fair value is just a modest estimate.
 Useful To Me  Not Useful To Me
keepnosecrets
Master
09-Sep-2009 16:50     
 
keepnosecrets About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Think 74 cents Fair value is just a modest estimate.
 Useful To Me  Not Useful To Me
lostbell
Member
09-Sep-2009 16:30     
 
lostbell About Contact  Quote this Post! Style: Technical   Mood: happy
Yells: "GOD BLESS EVERYONE!!!"
  x 1
  x 0

 Alert Admin

Biosensors International Group: Positive industry outlook. Maintain BUY.

Improving industry prospects

industry has yielded encouraging results. DES usage has risen to the

mid-70% range (vs ~65% year ago). While there are still proponents and

opponents to DES usage, rising clinical usage indicate that practitioners

are more comfortable with the significant research put in for the last three

years. Even less sanguine opponents of DES usage like Dr Edoardo

Camenzind* said to "resist short-term (marketing) distractions and stick

with (products with good) medical evidence". Biosensors possesses positive

"medical evidence" and we expect its next update in end Sep 09 at a

clinical conference to be encouraging.. Our scan of the Drug Eluting Stent (DES)

Peer group scan.

has been gaining market share. Along with Boston Scientifics' Promus

DES (sub-licensed Abbott DES platform), market watchers estimate that

the

lose market share with its older

with its

platform is estimated to command market share in the mid-teens. The

battle continues to be intense but the trend for technological superiority is

sustained. We believe that the current iteration for clinicians to stick to

products with strong clinical data will bode well for Biosensors' BioMatrix

DES which is authenticated by strong clinical data.Abbott's Xience V DES is now the key product thatXience V platform has >50% market share in the US. JnJ continues toCypher DES but is hoping to roar backNevo DES (but likely only in 2010). Medtronic's Endeavour DES

Pricing pressure not for premium products

webcasts indicate that ASP pricing pressures for DES have come more

from hospitals vs. peers engaging in a price undercutting war. Abbott's

management indicated that its newer generation Xience V DES have been

sustaining ASPs. Our previous checks with Biosensors indicate that ASPs

have been holding up in the EU markets.. Abbott's and JnJ's 2Q

M&A exit.

M&A situation. Adequate intellectual property protection, superior

technology and a well-executed product launch has catapulted Biosensors

onto the radar screens of the big boys. However, we think the company

may need significantly more cash and people bandwidth to sustain its

growth trajectory past FY11F. Our bets for future acquirers are Medtronic

(lagging technology pipeline) and Terumo (Asian based powerhouse and

current Biosensors' licensee). Maintain We still believe a key exit for long-term investors will be anBUY at S$0.74 fair value.

 Useful To Me  Not Useful To Me
allright
Senior
09-Sep-2009 15:53     
 
allright About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

from OCBC research

Biosensors International Group: Positive industry outlook. Maintain BUY.

Summary: Our scan of the Drug Eluting Stent (DES) industry has yielded encouraging results. DES usage has risen to the mid-70% range (vs. ~65% year ago). While there are still proponents and opponents to DES usage, rising clinical usage indicate that practitioners are more comfortable with the significant research put in for the last three years. Our scan of Biosensors’ peer group revealed a tough battleground in the US DES market. Abbott’s technology continues to gain ground while Medtronic and JnJ struggle to keep up. Clinicians being advocated to “resist short-term distractions and stick with medical evidence” will bode well for Biosensors’ BioMatrix DES which is authenticated by strong clinical data. ASPs have largely held up well. We still believe a key exit for long-term investors will be an M&A situation and think the company may need significantly more cash and people bandwidth to sustain its growth trajectory past FY11F. Our bets for future acquirers are Medtronic (lagging technology pipeline) and Terumo (Asian-based powerhouse and current Biosensors’ licensee). Maintain BUY at S$0.74 fair value. See Exhibit 2 for our “blue-sky” M&A assumptions.
 Useful To Me  Not Useful To Me
                                                         First   < Newer   4321-4340 of 10899   Older>   Last  



ShareJunction Version: 27 Nov 2020 ver- All Rights Reserved. Copyright ShareJunction Pte. Ltd. Disclaimer: All prices from are delayed. ShareJunction does not provide you with any financial advice. We are not into the business of providing any investment advice. See our Terms and Conditions and Privacy Policy of using this website. Data is delayed for varying periods of time depending on the exchange, but for at least 15 minutes. Copyright © SIX Financial Information Ltd. and its licensors. All Rights reserved. Further distribution and use by third parties prohibited. SIX Financial Information and its licensors make no warranty for information displayed and accept no liability for data and prices. SIX Financial Information reserves the right to adapt and/or alter this website at any time without prior notice.

Web design by FoundationFlux. Hosted with Signetique Cloud.